Stryker Expands Neuro Line With Synergetics Portfolio Buy
This article was originally published in The Gray Sheet
Executive Summary
Stryker added to its neuro device mix with the acquisition of Synergetics USA's portfolio, leaving the firm's ophthalmic device line with Valeant Pharmaceuticals.